Bowenoid Papulosis
Bowenoid papulosis (BP) is a distinctive form of squamous cell carcinoma in situ (SCC in situ) that affects the mucosal and semimucosal skin of the genital and perianal region. It occurs in both men and women, mostly during the sexually active years (ages 20–40).
What makes BP both unusual and challenging is the striking mismatch between how harmless it looks and how worrying it appears under the microscope:
- Clinically: single or multiple small reddish-brown or dark papules that closely resemble benign genital warts (condyloma acuminata).
- Histologically: the lesions show every feature of in situ malignancy and look identical to Bowen's disease (SCC in situ), with atypical keratinocytes throughout the full thickness of the epidermis and a high mitotic rate.
At Haute-Derma, we manage bowenoid papulosis with accurate histologic diagnosis, high-risk HPV genotyping and a treatment plan designed to protect appearance and genital function. The goal is to reduce the risk of malignant progression while keeping scarring and tissue distortion to a minimum.
Clinical and Pathologic Features
Pathogenesis and HPV Types
- Underlying cause: BP is directly linked to chronic infection with sexually transmitted high-risk strains of human papillomavirus (HPV).
- Common virus types: HPV-16 is the main culprit, found in more than 80% of cases. Other high-risk types include HPV-18, 31, 33, 35, 39, 45, 51 and 52.
- Disease mechanism: The E6 and E7 oncoproteins of high-risk HPV switch off two key tumor suppressors, p53 and pRb (retinoblastoma protein), respectively. With these brakes removed, keratinocytes proliferate unchecked, accumulate mutations and become dysplastic.
Clinical Features
- Who gets it: Mostly sexually active young adults (20–40 years), with men and women affected about equally.
- Appearance:
- Small (2–10 mm) flat or slightly raised papules with a smooth or faintly velvety surface; they are rarely as rough as typical genital warts.
- Color varies from pink or pale gray to reddish-brown, deep red or brown-black (pigmented variant).
- Lesions are usually multifocal and grouped in clusters.
- Typical sites:
- Men: penile shaft, coronal sulcus, foreskin, rim of the glans and perianal skin.
- Women: labia majora, labia minora, clitoris, perineum and perianal skin.
- Natural course: Despite its malignant appearance under the microscope, BP generally behaves more gently than classic Bowen's disease. In people with normal immunity, lesions may clear on their own over months to years. In immunocompromised patients or those with persistent HPV infection, however, about 1–3% progress to invasive squamous cell carcinoma.
Histopathology
Under the microscope, bowenoid papulosis cannot be told apart from Bowen's disease:
- Full-thickness atypia: basal and spinous keratinocytes have large, hyperchromatic, irregular nuclei and have lost their normal orientation.
- Frequent and abnormal mitoses: both normal and atypical mitotic figures are seen, including in the upper epidermis.
- Dyskeratotic cells: scattered prematurely keratinized cells with deeply eosinophilic cytoplasm.
- Intact basement membrane: the basement membrane is continuous, with no invasion.
- Signs of HPV infection: koilocytes may be present in the superficial epidermis, though usually less obvious than in ordinary genital warts.
Differential Diagnosis and Immunohistochemistry (IHC)
| Condition | Distinguishing Histology and IHC / Molecular Markers |
|---|---|
| Bowenoid papulosis (BP) | Multifocal genital papules; full-thickness epidermal atypia; strong, diffuse p16INK4a (+) throughout the epidermis; p53 (+); Ki-67 (+ full thickness); HPV-16/18 (+). |
| Genital warts (condyloma acuminata) | Benign papillary hyperplasia with abundant koilocytes; no atypical cells or abnormal mitoses; p16 (– or only focal); HPV-6/11 (+) (low-risk types). |
| Bowen's disease / erythroplasia of Queyrat | Usually a single large plaque in older adults; full-thickness atypia; p16 (+/–); p53 (+); associated with UV, arsenic or HPV. |
| Genital lichen planus | Band-like lymphocytic infiltrate at the dermoepidermal junction; basal cell degeneration with Civatte bodies; p16 (–); low Ki-67. |
| Melanoma in situ | Nests of atypical melanocytes in the epidermis; SOX10 (+); Melan-A (+); S100 (+); p16 (–). |
Our Approach to Treating Bowenoid Papulosis
Our treatment plans for bowenoid papulosis aim for the right balance between complete clearance, good cosmetic results and preserved function:
- Avoiding extensive, disfiguring surgery: Most patients are young and lesions are often multiple on genital mucosa. Wide surgical excision would cause unnecessary scar contracture, anatomic distortion and sexual dysfunction.
- Combining targeted destruction with immune therapy: Precise surface ablation is paired with immune-stimulating topical treatment to clear latent HPV in the surrounding skin.
- Screening sexual partners: Because high-risk HPV is involved, female partners need cervical screening (Pap smear / HPV testing) and male partners an anogenital examination.
How We Diagnose Bowenoid Papulosis at Haute-Derma
- Clinical examination and genital dermoscopy: We look for typical dermoscopic clues: a velvety papular surface and dotted or glomerular (coiled) vessels on a light reddish-brown background, with a well-defined border.
- Punch biopsy for histopathology: Required to confirm the diagnosis and to distinguish BP from benign genital warts or invasive squamous cell carcinoma.
- p16INK4a immunostaining and HPV genotyping:
- p16INK4a staining: a marker of high-risk HPV integration into the host genome. Strong, diffuse (block) positivity confirms HPV-driven dysplasia.
- HPV genotyping by PCR: identifies the exact HPV type (HPV-16, 18, etc.) to help estimate the long-term outlook.
- Immune status and related cancer screening: testing for HIV and other sexually transmitted infections, plus advice on cervical and anal screening.
Specialized Treatments at Haute-Derma
Treatment aims to remove visible papules, lower the chance of recurrence and prevent malignant transformation:
- Minimally invasive local destruction:
- UltraPulse CO2 laser: our first-line option. It vaporizes each papule precisely, with depth controlled to the micrometer, limiting damage to healthy tissue below. Bleeding is minimal and healing is cosmetically good.
- Liquid nitrogen cryotherapy: applied directly to small papules.
- Curettage and light electrodesiccation: used for clearly raised papules.
- Topical field therapy:
- Imiquimod 5% cream: an immune modulator that prompts the skin to produce interferon-alpha and TNF-alpha so the body can clear HPV and dysplastic cells. Applied 3 times a week for 8–16 weeks, it has a high response rate and lowers the risk of recurrence.
- Topical cidofovir / 5-fluorouracil (5-FU): reserved for resistant or very extensive disease.
- Photodynamic therapy (PDT):
- The photosensitizer 5-ALA is applied and left on for 3 hours, then the area is treated with red light (630 nm). PDT selectively destroys cells infected with high-risk HPV across the whole genital mucosa and rarely leaves a scar.
